Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven D Nathan

Showing results (271-280 of 297) with videos related to

Pageof 30
Sort By:
Open Forum Infectious Diseases|April 21, 2025
SARS-CoV-2 Immune Complex-Mediated Neutrophil ActivationKiana C Allen, Seth Warner, Heather L Teague, et al.
The New England Journal of Medicine|May 18, 2026
Phase 3 Trials of Inhaled Treprostinil for Idiopathic Pulmonary FibrosisSteven D Nathan, Peter Smith, Chunqin Deng, et al.
Pulmonary Circulation|October 16, 2023
Pulmonary hemodynamics and transplant-free survival in sarcoidosis-associated pulmonary hypertension: Results from an international registryShameek K Gayen, Robert P Baughman, Steven D Nathan, et al.
The Lancet. Respiratory Medicine|February 23, 2025
Future treatment paradigms in pulmonary arterial hypertension: a personal view from physicians, health authorities, and patientsFranck F Rahaghi, Marc Humbert, Marius M Hoeper, et al.
Journal of Intensive Care Medicine|September 13, 2024
Plasma Adsorption with the MTx.100 Column in Critically Ill COVID-19 Patients: A Prospective Study and Propensity Score AnalysisChristopher Choi, Nicole De Simone, Christopher B Webb, et al.
Respiratory Medicine|June 3, 2018
Clinical features of sarcoidosis associated pulmonary hypertension: Results of a multi-national registryRobert P Baughman, Oksana A Shlobin, Athol U Wells, et al.
Plos One|March 12, 2020
Targeting the Wnt signaling pathway through R-spondin 3 identifies an anti-fibrosis treatment strategy for multiple organsMingjun Zhang, Michael Haughey, Nai-Yu Wang, et al.
Thorax|March 13, 2016
Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosisSteven D Nathan, Carlo Albera, Williamson Z Bradford, et al.
Science Advances|January 4, 2023
Spleen tyrosine kinase inhibition restores myeloid homeostasis in COVID-19Gustaf Wigerblad, Seth A Warner, Marcos J Ramos-Benitez, et al.
Annals of Internal Medicine|May 8, 2013
Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trialGanesh Raghu, Juergen Behr, Kevin K Brown, et al.
Pageof 30

Showing results (271-280 of 297) with videos related to

Sort By:
Pageof 30
Open Forum Infectious Diseases|April 21, 2025
SARS-CoV-2 Immune Complex-Mediated Neutrophil ActivationKiana C Allen, Seth Warner, Heather L Teague, et al.
The New England Journal of Medicine|May 18, 2026
Phase 3 Trials of Inhaled Treprostinil for Idiopathic Pulmonary FibrosisSteven D Nathan, Peter Smith, Chunqin Deng, et al.
Pulmonary Circulation|October 16, 2023
Pulmonary hemodynamics and transplant-free survival in sarcoidosis-associated pulmonary hypertension: Results from an international registryShameek K Gayen, Robert P Baughman, Steven D Nathan, et al.
The Lancet. Respiratory Medicine|February 23, 2025
Future treatment paradigms in pulmonary arterial hypertension: a personal view from physicians, health authorities, and patientsFranck F Rahaghi, Marc Humbert, Marius M Hoeper, et al.
Journal of Intensive Care Medicine|September 13, 2024
Plasma Adsorption with the MTx.100 Column in Critically Ill COVID-19 Patients: A Prospective Study and Propensity Score AnalysisChristopher Choi, Nicole De Simone, Christopher B Webb, et al.
Respiratory Medicine|June 3, 2018
Clinical features of sarcoidosis associated pulmonary hypertension: Results of a multi-national registryRobert P Baughman, Oksana A Shlobin, Athol U Wells, et al.
Plos One|March 12, 2020
Targeting the Wnt signaling pathway through R-spondin 3 identifies an anti-fibrosis treatment strategy for multiple organsMingjun Zhang, Michael Haughey, Nai-Yu Wang, et al.
Thorax|March 13, 2016
Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosisSteven D Nathan, Carlo Albera, Williamson Z Bradford, et al.
Science Advances|January 4, 2023
Spleen tyrosine kinase inhibition restores myeloid homeostasis in COVID-19Gustaf Wigerblad, Seth A Warner, Marcos J Ramos-Benitez, et al.
Annals of Internal Medicine|May 8, 2013
Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trialGanesh Raghu, Juergen Behr, Kevin K Brown, et al.
Pageof 30